Search results for "DIABETES MELLITUS"

showing 10 items of 2077 documents

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations fr…

2022

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have …

Diabetes Mellitus Type 2Cardiovascular DiseasesGlucagon-Like Peptide 1HumansHypoglycemic AgentsAlgorithm Cardiovascular outcomes trials GLP-1 receptor agonists Treatment Type 2 diabetes mellitusLiraglutideCardiology and Cardiovascular MedicineAlgorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.Glucagon-Like Peptide-1 ReceptorInternational Journal of Cardiology
researchProduct

Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes.

2022

Diabetes Mellitus Type 2Drugs GenericHumansHypoglycemic AgentsPharmacology (medical)General MedicineGeneral Pharmacology Toxicology and PharmaceuticsLiraglutideBiosimilar PharmaceuticalsGlucagon-Like Peptide-1 ReceptorBiosimilar GLP-1 diabetes generics liraglutide treatmentExpert review of clinical pharmacology
researchProduct

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review

2022

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity. The reliable models that might predict weight reducing potential at the individual level have not been identified yet. However, the coexistence of diabetes has been consistently related with less effective response than in people without this comorbidity. We aimed to review the efficacy of GLP-1 RAs approved for weight management in individuals with and without diabetes and discuss some potential mechanisms for consistently observed differences in efficacy between these two populations. The mean weight loss difference between…

Diabetes Mellitus Type 2Glucagon-Like Peptide 1Weight LossGlucagon-Like PeptidesDiabetes GLP-1 RAs Liraglutide Obesity SemaglutideHumansHypoglycemic AgentsPharmacology (medical)ObesityGeneral MedicineLiraglutideWeight GainGlucagon-Like Peptide-1 Receptor
researchProduct

Treating equivalent cases differently: A comparative analysis of substance use disorder and type 2 diabetes in Norwegian treatment guidelines

2022

Background Substance use disorder (SUD) is often understood as a chronic illness. Aims: This paper investigates whether SUD is treated as a chronic illness. Method To this aim, we have used World Health Organizations (WHO's) definition of chronic illness to conduct a comparative analysis of SUD and type 2 diabetes (T2D), which is another chronic illness. Results When analysing Norwegian treatment guidelines, we found that only the T2D guideline reflects the WHO's conceptualization of chronic illnesses. We argue that this discrepancy implies that SUD is understood as a moral and legal problem, while T2D is conceptualized as a somatic illness. We discuss how social, political and historical c…

Diabetes Mellitus Type 2Substance-Related Disorders:Medisinske Fag: 700 [VDP]Health Policymental disordersPublic Health Environmental and Occupational HealthHumansWorld Health OrganizationVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850behavioral disciplines and activitieshealth care economics and organizationshumanities
researchProduct

Quantitative corneal anatomy: evaluation of the effect of diabetes duration on the endothelial cell density and corneal thickness.

2014

Purpose To evaluate the differences in endothelial cell density (ECD) and central corneal thickness (CCT) between type II diabetic patients and age-matched healthy controls, and determine the impact of time from diagnosis. Methods This is a comparative study of 77 eyes of type II diabetic patients (33 males, 44 females) and 80 eyes of healthy subjects (42 males, and 38 females) whose ages ranged from 38 to 56 years. CCT, ECD, HbA1c levels, and Goldmann tonometry were measured. Results The CCT was significantly higher and the ECD significantly lower in long-term diabetic patients (10 years + since diagnosis) when compared with short-term diabetic patients (<1 year since diagnosis) and contro…

Diabetes durationAdultMalemedicine.medical_specialtyTime Factorsgenetic structuresCorneal PachymetryCell CountType ii diabetesCorneaHba1c levelOphthalmologyInternal medicineMedicineHumansRetrospective StudiesGlycated Hemoglobinbusiness.industryEndothelium CornealHealthy subjectsMiddle AgedCorneal structureeye diseasesSensory SystemsEndothelial cell densityGoldmann tonometryOphthalmologyEndocrinologyDiabetes Mellitus Type 2Disease ProgressionFemalesense organsAnalysis of variancebusinessOptometryOphthalmicphysiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
researchProduct

Diabetes and cognitive decline

2022

Epidemiologic studies have documented an association between diabetes and increased risk of cognitive decline in the elderly. Based on animal model studies, several mechanisms have been proposed to explain such an association, including central insulin signaling, neurodegeneration, brain amyloidosis, and neuroinflammation. Nevertheless, the exact mechanisms in humans remain poorly defined. It is reasonable, however, that many pathways may be involved in these patients leading to cognitive impairment. A major aim of clinicians is identifying early onset of neurologic signs and symptoms in elderly diabetics to improve quality of life of those with cognitive impairment and reduce costs associa…

Diabetes mellituAmyloid beta-Peptidestau ProteinsAmyloid beta-peptideBiomarkerAmyloidosisVascular dementiaSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaDiabetes mellitusGlycated hemoglobinSettore MED/13Alzheimer DiseaseTau proteinQuality of LifeBlood glucoseHumansDementiaCognitive DysfunctionBiomarkersRisk assessmentAged
researchProduct

Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project

2022

Background and aim: The URRAH (URic acid Right for heArt Health) Study has identified cut-off values of serum uric acid (SUA) predictive of total mortality at 4.7 mg/dl, and cardiovascular (CV) mortality at 5.6 mg/dl. Our aim was to validate these SUA thresholds in people with diabetes. Methods and results: The URRAH subpopulation of people with diabetes was studied. All-cause and CV deaths were evaluated at the end of follow-up. A total of 2570 diabetic subjects were studied. During a median follow-up of 107 months, 744 deaths occurred. In the multivariate Cox regression analyses adjusted for several confounders, subjects with SUA ≥5.6 mg/dl had higher risk of total (HR: 1.23, 95%CI: 1.04-…

Diabetes mellituNutrition and DieteticsSettore MED/09 - Medicina InternaCardiovascular mortalitySerum uric acid Cardiovascular mortality All-cause mortality Diabetes mellitus Hyperuricemia Diagnostic thresholdsEndocrinology Diabetes and MetabolismMedicine (miscellaneous)HyperuricemiaAll-cause mortalityUric AcidDiagnostic thresholdsall-cause mortality; cardiovascular mortality; diabetes mellitus; diagnostic thresholds; hyperuricemia; serum uric acid; humans; risk factors; uric acid; diabetes mellitus; hyperuricemiaDiagnostic thresholdDiabetes mellitusSerum uric acidRisk FactorsAll-cause mortality; Cardiovascular mortality; Diabetes mellitus; Diagnostic thresholds; Hyperuricemia; Serum uric acidHumansCardiology and Cardiovascular Medicine
researchProduct

Self-concept and adaptation to illness in pediatric diabetic patients

2014

Nuestro objetivo es estudiar el autoconcepto y la adaptación a la enfermedad en pacientes pediátricos diabéticos. Como instrumentos de evaluación se utilizaron el registro ad-hoc para las variables sociodemográficas y de enfermedad, el cuestionario de Autoconcepto Garley (CAG) y cuestionario de respuesta adaptativa a la enfermedad en pacientes diabéticos. La muestra constó de 23 sujetos evaluados en un único momento de medida, todos ellos niños y adolescentes entre 8 y 16 años de edad. Los resultados muestran cómo aproximadamente el 50% de niños y adolescentes con diabetes tipo I presentan un autoconcepto bajo en la mayoría de las dimensiones estudiadas, destacando cómo cerca del 30% de los…

Diabetes mellitus insulinodependienteAutoconceptoAdaptaciónSelf-conceptDiseaseAdaptationInsulin-dependent diabetesEnfermedad
researchProduct

Metilación del ADN de adipocitos en sujetos con obesidad mórbida

2019

Introducción: La obesidad y la diabetes mellitus tipo 2 (DM2) son dos patologías con elevada prevalencia e importante morbimortalidad asociada en nuestro medio. La obesidad, mediante diferentes mecanismos en los que juega un importante papel el tejido adiposo, se asocia con resistencia a la insulina, la cual suele preceder a la aparición de diabetes mellitus tipo 2. Existen alteraciones genéticas que predisponen al desarrollo de resistencia a la insulina y DM2 en pacientes con obesidad, pero no explican la totalidad del riesgo. Se postula que la epigenética, que se define como modificaciones heredables sobre los genes que varían su función sin necesidad de alteración de la secuencia de ADN,…

Diabetes mellitus tipo 2AdipocitosObesidad mórbida:CIENCIAS MÉDICAS ::Medicina interna::Endocrinología [UNESCO]EpigenéticaUNESCO::CIENCIAS MÉDICAS ::Medicina interna::Endocrinología
researchProduct

Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study

2022

Although it is well known that lifestyle changes can affect plasma glucose levels, there is little formal evidence for the sustained effectiveness of exercise and diet in diabetes mellitus (DM) management. Self-care in DM refers to the real-life application of the knowledge that the patient gained during the education programmes. The goals are to bring about changes in the patient&rsquo;s behaviour, thus improving glycaemic control. We evaluated the influence of DM self-care activities (SCA) on glycaemic control in a total of 159 patients with DM. Plasma glycated haemoglobin (HbA1c) levels were used to monitor glycaemic control, while SCA were assessed using the standardised Diabetes Self-M…

Diabetes mellitus Diabetes self-management questionnaire Glycaemic control Physical activity Prevention Self-care activitiesdiabetes mellitus; diabetes self-management questionnaire; physical activity; self-care activities; glycaemic control; preventionLeadership and ManagementHealth PolicyRphysical activityHealth Informaticsself-care activitiesArticleglycaemic controlpreventionHealth Information Managementdiabetes mellitusMedicinediabetes self-management questionnaire
researchProduct